Form 4: Arcadia Biosciences CEO Thomas J. Schaefer Reports Stock Option Grant
SEC Form 4 Filing
Arcadia Biosciences CEO Thomas J. Schaefer reports the acquisition of stock options.
Summary
- Thomas J. Schaefer, CEO of Arcadia Biosciences, reported a transaction involving derivative securities.
- On August 19, 2024, Schaefer acquired stock options for 20,000 shares of common stock at an exercise price of $2.71.
- These options vest over time, with 25% vesting on the first anniversary of the grant date and the remaining 75% vesting in 36 equal monthly installments.
- Following the reported transaction, Schaefer directly owns 25,475 derivative securities.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing related to executive compensation, and does not contain any information that would significantly impact investor sentiment positively or negatively.
Positives
- The granting of stock options to the CEO can be seen as an incentive to align his interests with those of the shareholders.
Industry Context
This is a standard practice for publicly traded companies to compensate executives with stock options, aligning their interests with shareholders.
Stakeholder Impact
- The granting of stock options aligns the CEO's interests with those of the shareholders, potentially incentivizing him to increase shareholder value.
Key Dates
| Date | Description |
|---|---|
| 08/19/2024 | Date of stock option grant and transaction. |
| 08/19/2034 | Expiration date of the stock options. |
| 08/21/2024 | Date of Form 4 filing. |
Keywords
stock options, derivative securities, Form 4, Arcadia Biosciences, RKDA, CEO, Thomas J. Schaefer, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.